285 related articles for article (PubMed ID: 11098485)
41. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
42. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
[TBL] [Abstract][Full Text] [Related]
43. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
44. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
[TBL] [Abstract][Full Text] [Related]
45. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
[TBL] [Abstract][Full Text] [Related]
46. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
47. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
48. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
49. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
[TBL] [Abstract][Full Text] [Related]
50. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
[TBL] [Abstract][Full Text] [Related]
51. [Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():144-9. PubMed ID: 16897991
[TBL] [Abstract][Full Text] [Related]
52. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
53. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
54. Oral fluoropyrimidines: a closer look at their toxicities.
Macdonald JS
Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
[TBL] [Abstract][Full Text] [Related]
55. Biochemical and clinical pharmacology of 5-fluorouracil.
Schilsky RL
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):13-8. PubMed ID: 9830619
[TBL] [Abstract][Full Text] [Related]
56. Clinical development of eniluracil: current status.
Hohneker JA
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
[TBL] [Abstract][Full Text] [Related]
57. Other fluorinated pyrimidines in the treatment of solid tumors.
Saad ED; Hoff PM
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):65-8. PubMed ID: 11219980
[TBL] [Abstract][Full Text] [Related]
58. UFT and S-1 for treatment of primary lung cancer.
Tanaka F; Wada H; Fukushima M
Gen Thorac Cardiovasc Surg; 2010 Jan; 58(1):3-13. PubMed ID: 20058135
[TBL] [Abstract][Full Text] [Related]
59. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
60. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
